Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Keyphrases

• Low-density Lipoprotein Cholesterol (LDL-C) 100%
• LDL Cholesterol 100%
• Lipoproteins 100%
• Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) 100%
• Acute Coronary Syndrome 75%
• Alirocumab 75%
• Statin Treatment 75%
• Odyssey 50%
• Proprotein 50%
• Placebo 25%
• Statin Therapy 25%
• Hazard Ratio 25%
• Clinical Benefit 25%
• Major Adverse Cardiovascular Events 25%
• Cardiovascular Outcomes 25%
• Ultra-high Risk 25%
• Residual Risk 25%
• Non-statins 25%
• Lipid-lowering Agents 25%
• Maximum Tolerated 25%
• Low-density Lipoprotein Cholesterol Level 25%
• During Treatment 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Lipoprotein A 100%
• Low Density Lipoprotein Cholesterol 100%
• Statin (Protein) 66%
• Acute Coronary Syndrome 50%
• Alirocumab 50%
• Subtilisin 33%
• Kexin 33%
• Placebo 16%
• Antilipemic Agent 16%
• Cardiovascular Disease 16%